Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphomaPierre Stéphan, Jennifer L. Crombie, Christopher R. Flowers et al.|Blood|2025Cited by 0
Outcomes of CD20 Bispecific Antibodies after CD19 CAR T-cell Therapy in mantle cell lymphoma: A Multicenter Analysis from the Collaborative U.S. Bispecific Consortium (CUBIC)Ajay Major, Andrew Jallouk, Amy Ayers et al.|Transplantation and Cellular Therapy|2026Cited by 0